New radiation technique aims to cut side effects in prostate cancer treatment
NCT ID NCT02918253
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether giving high-dose radiation only to the tumor area (focal HDR brachytherapy) can control early-stage prostate cancer while causing fewer side effects than treating the whole gland. Sixty men with low- or favorable intermediate-risk prostate cancer will receive this targeted radiation. The main goal is to see if the cancer stays under control, while also checking for improvements in urinary, bowel, and sexual function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
high-dose rate (HDR) brachytherapy (radiation)
What this could lead to
If successful, this approach could offer a way to treat early-stage prostate cancer with fewer urinary, rectal, and sexual side effects, improving quality of life.
What could go wrong
This is a small feasibility study (60 people) with no phase designation, so results are preliminary. It may not show clear benefits or could still cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada